Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 3, 2008, Pages 267-277

  Shokeen, M ^a   Fettig, N M ^a   Rossin, Raffaella ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

In vitro in vivo evaluation; Nanoparticles; PET radionuclides

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOCHEMICAL MARKER; BROMINE 76; CARBON 14; COPPER 64; INDIUM 111; IODINE 124; IODINE 125; NANOPARTICLE; POLYACRYLAMIDE; POLYSTYRENE; RADIOISOTOPE; TECHNETIUM 99M; TRIENTINE; TRITIUM; VITRONECTIN RECEPTOR;

CELL STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TARGETING; EX VIVO STUDY; FAST PROTEIN LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR PROBE; NANOMEDICINE; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PURIFICATION; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS; THIN LAYER CHROMATOGRAPHY;

BROMINE RADIOISOTOPES; CHROMATOGRAPHY, LIQUID; CHROMATOGRAPHY, THIN LAYER; COPPER RADIOISOTOPES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; IODINE RADIOISOTOPES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 48749089219     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006;58:1532-55.
2. Duncan R. Targeting and intracellular delivery of drugs. Encyclopedia of Molecular Cell Biology and Molecular Medicine, 2nd ed. Weinheim: Wiley-VCH; 2005.p. 163-203.
3. Carver LA, Schnitzer JE. Caveolae: mining tittle caves for new cancer targets. Nat Rev Cancer 2003;3:571-81.
4. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207.
5. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
6. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007;18:26-30.
7. Sosnovik DE, Weissleder R. Emerging concepts in molecular MRI. Curr Opin Biotechnol 2007;18:4-10.
8. Torchilin VP. Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol 2000;1:183-215.
9. 3H]methotrexate in a primate. Cancer Res 1976;36:2949-57.
10. Seymour LW, Duncan R, Strohalm J, Kopecek J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res 1987;21:1341-58.
11. Sjoholm I, Edman P. Acrylic microspheres in vivo: distribution and elimination of polyacrylamide microparticles after intravenous and intraperitoneal injection in mouse and rat. J Pharmacol Exp Ther 1979;211:656-62.
12. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7:243-54.
13. Laverman P, Boerman OC, Oyen WJG, Dams ETM, Storm G, Corstens FHM. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999;37:225-35.
14. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60.
15. Laverman P, Carstens MG, Storm G, Moghimi SM. Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity: Implications in experimental and clinical oncology. Biochim Biophys Acta 2001;1526:227-9.
16. 99mTc by the hydrazino nicotinyl derivative. J Nucl Med 1999;40:192-7.
17. Gref T, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994;263:1600-3.
18. Jestin E, Mougin-Degraef M, Faivre-Chauvet A, Remaud-Le Saec P, Hindre F, Benoit JP et al. Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapy. Q J Nucl Med Mol Imaging 2007;51:51-60.
19. Kommareddy S, Amiji M. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J Pharm Sci 2007;96:397-407.
20. Rolland A, Collet B, Le Verge R, Toujas L. Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J Pharm Sci 1989;78:481-4.
21. Cartier R, Kaufner L, Paulke BR, Stneck R, Pietschmann S, Michel R et al. Latex nanoparticles for multimodal imaging and detection in vivo. Nanotechnology 2007;18:195102.
22. 188Re-labelled lipid nanocapsules as promising radio-tracers for imaging and therapy: formulation and biodistribution. Fur J Nucl Med Mol Imaging 2006; 33:602-7.
23. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling and biodistribution studies. AAPS J 2004;6:e23.
24. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A 2006;103:3357-62.
25. Weissleder R, Lee AS, Fischman AJ, Reimer P, Shen T, Wilkinson R et al. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging. Radiology 1991;181:245-9.
26. Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 2002;13:264-8.
27. Kaufner L, Cartier R, Stneck R, Fichtner I, Pietschmann S, Bruhn H et al. Poly(ethylene oxide)-block-poly(glutamic acid) coated maghemite nanoparticles: in vitro characterization and in vivo behaviour. Nanotechnology 2007;18:115710.
28. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Contr Rel 2004;95:613-26.
29. Cao J, Wang Y, Yu J, Ma J, Zhang C, Yin D et al. Preparation and radiolabeling of surface-modified magnetic nanoparticles with rhenium-188 for magnetic targeted radiotherapy. J Magn Magn Mater 2004;277:165-74.
30. 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003;44:1992-9.
31. Banerjee T, Singh AK, Sharma RK, Maitra AN. Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: interference by colloidal tin oxide particles. Int J Pharm 2005;289:189-95.
32. 188Re for bio-magnetically targeted radiotherapy. J Radioanal Nucl Chem 2006;269:3-7.
33. 64Cu-labeled nanoparticles targeted to the lung endothelium. J Nucl Med 2008;49:103-11.
34. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 2005;46:1210-8.
35. Sun X, Rossin R, Turner JL, Becker ML, Joralemon MJ, Welch MJ et al. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 2005;6:2541-54.
36. Bartlett DW, Su H, Hildebrant IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007;104:15549-54.
37. Schipper ML, Cheng Z, Lee SW, Bentolila LA, Iyer G, Rao J et al. MicroPET-based biodistribution of quantum dots in living mice. J Nucl Med. 2007;48:1511-18.
38. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nano 2007;2:47-52.
39. 64Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules 2007;8:3126-34.
40. 64Cu conjugates for interventional radionuclide therapy of prostate cancer: assessment of intratumoral retention by microPET imaging. Mol Imaging 2007;6:10-7.
41. Adam MJ, Wilbur DS. Radiohalogens for imaging and therapy. Chem Soc Rev 2005;34:153-63.
42. Beattie BJ, Finn RD, Rowland DJ, Pentlow KS. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity induced by cascade gamma rays. Med Phys 2003;30:2410-23.
43. 86Y. Nucl Med Commun 2006;27:237-45.
44. Wadas TJ, Anderson CJ. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protocols 2007;1:3062-8.
45. Wadas TJ, Wong EH, Weisman GR, Anderson CJ, Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007;13:3-16.
46. Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol 2004;386:237-61.
47. Sun G, Xu J, Hagooly A, Rossin R, Li Z, Moore DA. Strategies for optimized radiolabelling of nanoparticles for in vivo PET imaging. Adv Mater 2007;19:3157-62.
48. Xu J, Sun G, Rossin R, Hagooly A, Li Z, Fukukawa K. Labeling of polymer nanostructures for medical imaging: importance of cross-lingking extent, spacer length, and charge density. Macromolecules 2007;40:2971-3.
49. Duncan R, Kopecek J, Rejmanova P, Lloyd JB. Targeting of N-(2-hydroxypropyl) methacrylamide copolymers to liver by incorporation of galactose residues. Biochim Biophys Acta 1983;755:518-21.
50. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Cancer Sci 1998;89:307-14.
51. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995;31:66-70.
52. Gillies ER, Dy E, Frechet JMJ, Szoka FC. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol Pharm 2005;2:129-38.
53. Muro S, Dziubla T, Qiu W, Leferovich J, Cui X, Berk E et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther 2006;317:161-9.
54. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003;116:1599-609.
55. Welch MJ, Redvanly CS, editors. Handbook of radiopharmaceuticals, radiochemistry and applications. Chirchester: John Wiley & Sons; 2003.
56. Ke T, Jeong EK, Wang X, Feng Y, Parker DL, Lu ZR. RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping. Int J Nanomedicine 2007;2:191-9.
57. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999;40:1061-71.
58. Sprague JE, Peng Y, Fiamengo AL, Woodin KS, Southwick EA, Weisman GR et al. Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents. J Med Chem 2007;50:2527-35.
59. Decuzzi P, Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 2007;28:2915-22.
60. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006;8:214-22.
61. Muñoz-Chápuli R, Quesada AR, Ángel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2004;61:2224-43.
62. Bloch S, Xu B, Ye Y, Liang K, Achilefu S. Internalization of RGD peptide conjugates of near-infrared fluorescent probes in different cell lines occurs via different integrin receptor subtypes. Proc SPIE 2006;6097:1-9.
63. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:54-63.
64. Kobayashi H, Lin PC. Nanotechnology for antiangiogenic cancer therapy. Nanomedicine 2006;1:17-22.
65. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 2006;12:2723-47.
66. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005;8:381-402.
67. Chen X. Multimodality imaging of tumor integrin ·v,3 expression. Mini Rev Med Chem 2006;6:227-34.
68. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110:2032-8.
69. 3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2103-9.
70. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Res Imaging 2007;25:667-80.
71. 99mTc]HYNIC-RGD for imaging integrin ·v,3 expression. Nucl Med Biol 2006;33:945-52.
72. Lindberg FP, Gresham HD, Reinhold MI, Brown EJ. Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. J Cell Biol 1996;134:1313-22.
73. Owens III DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102.